Trial Profile

CD19-CAR-T for Patients With B Cell Malignancies

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 03 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AVA 001 Avalon GloboCare (Primary) ; Cyclophosphamide; Fludarabine
Indications B-cell leukaemia; B-cell lymphoma; Haematological malignancies; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; First in man; Therapeutic Use

Most Recent Events

28 Jan 2022 Status changed from recruiting to completed.
01 Oct 2020 According to an Avalon GloboCare media release, the company is expanding this trial to recruit patients with relapsed/refractory Non-Hodgkin lymphoma (R/R-NHL).
29 Jun 2020 Results published an Avalon GloboCare media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com